We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.
- Authors
Dong, Mingjie; Liu, Xianqiong; Evert, Katja; Utpatel, Kirsten; Peters, Michele; Zhang, Shanshan; Xu, Zhong; Che, Li; Cigliano, Antonio; Ribback, Silvia; Dombrowski, Frank; Cossu, Antonio; Gordan, John; Calvisi, Diego F.; Evert, Matthias; Liu, Yan; Chen, Xin
- Abstract
Intrahepatic cholangiocarcinoma (iCCA) is a deadly malignancy with limited treatment options. Gain-of-function mutations in K-Ras is a very frequent alteration, occurring in ~15 to 25% of human iCCA patients. Here, we established a new iCCA model by expressing activated forms of Notch1 (NICD) and K-Ras (K-RasV12D) in the mouse liver (K-Ras/NICD mice). Furthermore, we investigated the therapeutic potential of MEK inhibitors in vitro and in vivo using human CCA cell lines and K-Ras/NICD mice, respectively. Treatment with U0126, PD901, and Selumetinib MEK inhibitors triggered growth restraint in all CCA cell lines tested, with the most pronounced growth suppressive effects being observed in K-Ras mutant cells. Growth inhibition was due to reduction in proliferation and massive apoptosis. Furthermore, treatment of K-Ras/NICD tumor-bearing mice with PD901 resulted in stable disease. At the molecular level, PD901 efficiently inhibited ERK activation in K-Ras/NICD tumor cells, mainly leading to increased apoptosis. Altogether, our study demonstrates that K-Ras/NICD mice represent a novel and useful preclinical model to study K-Ras-driven iCCA development and the effectiveness of MEK inhibitors in counteracting this process. Our data support the usefulness of MEK inhibitors for the treatment of human iCCA.
- Publication
Cell Death & Disease, 2018, Vol 9, Issue 2, p1
- ISSN
2041-4889
- Publication type
Article
- DOI
10.1038/s41419-017-0183-4